ENOS Antikörper (N-Term)
Kurzübersicht für ENOS Antikörper (N-Term) (ABIN652267)
Target
Alle ENOS (NOS3) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 48-75, N-Term
-
Homologie
- B, Pig
-
Aufreinigung
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This NOS3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from the N-terminal region of human NOS3.
-
Isotyp
- Ig Fraction
-
-
-
-
Applikationshinweise
- IF: 1:10~50. IHC-P: 1:10~50. FC: 1:10~50
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
-
Haltbarkeit
- 6 months
-
-
-
: "Oxidative stress and inhibition of nitric oxide generation underlie methotrexate-induced senescence in human colon cancer cells." in: Mechanisms of ageing and development, Vol. 170, pp. 22-29, (2018) (PubMed).
-
-
- ENOS (NOS3) (Nitric Oxide Synthase 3 (Endothelial Cell) (NOS3))
-
Andere Bezeichnung
- NOS3
-
Hintergrund
- Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases.
-
Molekulargewicht
- 133275
-
Gen-ID
- 4846
-
NCBI Accession
- NP_000594, NP_001153581, NP_001153582, NP_001153583
-
UniProt
- P29474
-
Pathways
- ACE Inhibitor Pathway, Regulation of Systemic Arterial Blood Pressure by Hormones, Cellular Response to Molecule of Bacterial Origin, Myometrial Relaxation and Contraction, Signaling Events mediated by VEGFR1 and VEGFR2, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling
Target
-